court ruling on tirzepatide US judge sides with FDA's removal of Lilly's weight loss drug from shortage list Readout Newsletter: Makary hearing, Hims,

Understanding their reasoning helps you determine whether its a legitimate clinical concern or something you can address

You are not a candidate if you are pregnant or trying for pregnancy, if you have any history of medullary thyroid cancer or multiple endocrine neoplasia

Clarifying Back Pain Versus Medication Effects Understanding the root cause of back pain in someone taking semaglutide is essential

Recent clinical data suggests that continuing or pausing your injection depends on symptom severity, hydration status, and individual tolerancenot a one-size-fits-all rule

According to NICE guidance (NG28) , GLP-1 receptor agonists like Trulicity are usually considered after failure of triple oral therapy and recommended for adults with type 2 diabetes who have inadequate glycaemic control and a body mass index (BMI) of 35 kg/m or higher (with adjustment for ethnicity where appropriate), or for those with a BMI lower than 35 kg/m when insulin therapy would have significant occupational implications or weight loss would benefit other obesity-related comorbidities